RT Journal Article
SR Electronic
T1 Placenta-derived conditioned medium with anti-tumor properties on human NSCLC
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA4983
DO 10.1183/13993003.congress-2015.OA4983
VO 46
IS suppl 59
A1 Lang, Dagmar S.
A1 Marwitz, Sebastian
A1 Zeiser, Tobias
A1 Seehase, Sophie
A1 Watermann, Iris
A1 Vollmer, Ekkehard
A1 Reck, Martin
A1 Zabel, Peter
A1 Goldmann, Torsten
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/OA4983.abstract
AB The decidua of human term placenta contains a cell population with highly immunomodulatory properties regulating viability, growth and invasion important for the fetal development, remarkably resembling the tumor-microenvironment. Prompted by previously published data from our group demonstrating the pro-apoptotic potential of placenta-derived supernatant on human lung cancer in vitro, the anti-tumor activity of placenta-conditioned medium was studied in more detail. For this purpose, human NSCLC cell lines A549 and H838 were challenged for 17h with placenta-derived conditioned medium, obtained from human fresh term placenta incubated overnight in DMEM with 2%FCS.Viability was analysed either by MTT assay or FACS using 7-AAD. For tumor growth, expression of proliferation marker Ki-67 was analysed, induction of apoptosis was determined by expression of annexin V and/or cleaved caspase 3 using immunofluorescence or FACS analysis. Overall, both suppression of Ki-67 expression and increase of apoptotic cells were induced by all placentas (n=6), although to strikingly varying extent. Based on these preliminary but promising results demonstrating consistent inhibitory effects on lung tumor cells, placenta-derived anti-tumor activity will be further studied including human NSCLC specimens and by using fractionated placenta-derived supernatants that will be also analysed by mass spectrometry to identify potential immunosuppressive mediators. Thus, these studies could result in the development of new therapeutic agents for a more effective treatment of NSCLC.